{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:58Z","timestamp":1789628518444,"version":"build-2803163510"},"reference-count":49,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,2,1]]},"abstract":"<jats:p> PURPOSE: To assess, in a multi-institutional setting, the impact on relapse, survival, and toxicity of adding two cycles of intravenous methotrexate to cranial irradiation for immunocompetent patients with primary CNS lymphoma. <\/jats:p><jats:p> PATIENTS AND METHODS: Forty-six patients with a median age of 58 years and Eastern Cooperative Oncology Group performance status 0 to 3 were entered onto this phase II study. The protocol consisted of methotrexate 1 g\/m<jats:sup>2<\/jats:sup> on days 1 and 8 followed by cranial irradiation on day 15. A whole-brain dose of 45 Gy was followed by a boost of 5.4 Gy. Intrathecal chemotherapy and spinal irradiation were given only to patients for whom cytologic examination of CSF was positive for CNS lymphoma. The median follow-up time was 36 months, with a minimum potential follow-up of 12 months. <\/jats:p><jats:p> RESULTS: Median survival was 33 months, with 2-year probability of survival 62% \u00b1 15% (95% confidence interval). Twenty patients have relapsed. The predominant site of relapse was the brain. Neither performance status nor age was found to influence survival. Six patients developed a dementing illness at a median of 16 months after treatment, and three of these died as a consequence. <\/jats:p><jats:p> CONCLUSION: A brief course of intravenous methotrexate before cranial irradiation is associated with 2-year and median survival rates superior to those reported for radiotherapy alone and similar to more intensive combined-modality regimens. Neurotoxicity remains an important competing risk for these patients. <\/jats:p>","DOI":"10.1200\/jco.2000.18.3.519","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:04:24Z","timestamp":1487919864000},"page":"519-519","source":"Crossref","is-referenced-by-count":193,"title":["Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma"],"prefix":"10.1200","volume":"18","author":[{"given":"P.","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roos","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pratt","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Liew","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barton","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Poulsen","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Olver","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Trotter","sequence":"additional","affiliation":[{"name":"From the Trans-Tasman Radiation Oncology Group: Department of Radiation OncologyNewcastle Mater Hospital, Newcastle, and Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales; Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia; Queensland Radium Institute, Royal Brisbane Hospital and Mater Hospital, Brisbane, Queensland; Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; and Department of Radiation Oncology, Waikato Hospital, Hamilton, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0070","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M"},{"key":"R2-0070","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.381"},{"key":"R3-0070","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2409::AID-CNCR17>3.0.CO;2-V"},{"key":"R4-0070","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058839"},{"key":"R5-0070","doi-asserted-by":"crossref","unstructured":"Bashir  R,  Freedman  A,  Harris  N, et al:  Immunophenotypic profile of CNS lymphoma:  A review of eighteen cases. J Neurooncol 7:249,1989-254,","DOI":"10.1007\/BF00172918"},{"key":"R6-0070","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831201)52:11<1993::AID-CNCR2820521104>3.0.CO;2-C"},{"key":"R7-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.4.490"},{"key":"R8-0070","doi-asserted-by":"crossref","unstructured":"Berry  MP,  Simpson  WJ:  Radiation therapy in the management of primary malignant lymphoma of the brain.  Int J Radiat Oncol Biol Phys 7:55,1981-59,","DOI":"10.1016\/0360-3016(81)90060-2"},{"key":"R9-0070","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1986.65.5.0600"},{"key":"R10-0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(85)80086-4"},{"key":"R11-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90538-S"},{"key":"R12-0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00571-3"},{"key":"R13-0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)00074-1"},{"key":"R14-0070","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B"},{"key":"R15-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.859"},{"key":"R16-0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00002-9"},{"key":"R17-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00207-F"},{"key":"R18-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.556"},{"key":"R19-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.945"},{"key":"R20-0070","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.81.2.0188"},{"key":"R21-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1580"},{"key":"R22-0070","doi-asserted-by":"publisher","DOI":"10.1007\/BF00869771"},{"key":"R23-0070","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1757"},{"key":"R24-0070","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.2.435"},{"key":"R25-0070","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900501)65:9<1907::AID-CNCR2820650906>3.0.CO;2-L"},{"key":"R26-0070","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.2922.2922"},{"key":"R27-0070","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1721"},{"key":"R28-0070","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1996.tb138578.x"},{"key":"R29-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(60)90137-5"},{"key":"R30-0070","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R31-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90416-2"},{"key":"R32-0070","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1946::AID-CNCR19>3.0.CO;2-T"},{"key":"R33-0070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.3000"},{"key":"R34-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90413-8"},{"key":"R35-0070","doi-asserted-by":"crossref","unstructured":"Crossen  JR,  Garwood  D,  Glatstein  E, et al:  Neurobehavioural sequelae of cranial irradiation in adults:  A review of radiation-induced encephalopathy. J Clin Oncol 627:642,1994-642,","DOI":"10.1200\/JCO.1994.12.3.627"},{"key":"R36-0070","doi-asserted-by":"publisher","DOI":"10.3109\/02841869609083995"},{"key":"R37-0070","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199604000-00028"},{"key":"R38-0070","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-84892-6_1"},{"key":"R39-0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)00063-7"},{"key":"R40-0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"R41-0070","unstructured":"DeAngelis  LM:  Current management of primary central nervous system lymphoma.  Oncology 9:63,1995-71,"},{"key":"R42-0070","doi-asserted-by":"publisher","DOI":"10.3109\/08880019009033410"},{"key":"R43-0070","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90009-3"},{"key":"R44-0070","doi-asserted-by":"crossref","unstructured":"Gilchrist  NL,  Caldwell  J,  Watson  ID, et al:  Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin\u2019s lymphoma.  Cancer Chemother Pharmacol 15:290,1985-294,","DOI":"10.1007\/BF00263903"},{"key":"R45-0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"R46-0070","unstructured":"Glick  JH,  Kim  K,  Earle  J, et al:  An ECOG randomized phase III trial of CHOP vs CHOP + radiotherapy for intermediate grade early stage non-Hodgkin\u2019s lymphoma.  Proc Am Soc Clin Oncol 14:391,1995  (abstr 1221)"},{"key":"R47-0070","unstructured":"McBride  NC,  Ward  MC,  Schey  S, et al:  Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin\u2019s lymphoma.  Proc Am Soc Hematol 92:621a,1998  (suppl 1, abstr A2560)"},{"key":"R48-0070","unstructured":"Forssen  EA,  Male-Brune  R,  Adler-Moore  JP, et al:  Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue.  Cancer Res 56:2006,1996-2075,"},{"key":"R49-0070","doi-asserted-by":"crossref","unstructured":"Albrecht  KS,  Leenstra  S,  Bakker  PJM, et al:  High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin.  Proc Am Soc Clin Oncol 16:388a,1997  (abstr 1385)","DOI":"10.1016\/S0303-8467(97)82346-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.3.519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:38:27Z","timestamp":1653514707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.3.519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,2,1]]}},"alternative-id":["10.1200\/JCO.2000.18.3.519"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.3.519","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,1]]}}}